Inclusion Criteria:

- Pathologically confirmed adenocarcinoma of the prostate

- Radiographic evidence of metastatic disease

- Progressive disease meeting at least one of the following criteria:

1. a sequence of at least 2 rising PSA values measured at a minimum of 1 week apart
with a 2 ng/mL minimum starting value, or

2. progression according to RECIST criteria for measurable lesions, or

3. appearance of 2 or more new lesions on bone scan.

- History of prior taxane-based chemotherapy for metastatic prostate cancer

- For patients without a history of surgical castration, continued GnRH analog
administration is required

- ECOG Performance status of 0 or 1

- Life expectancy ≥ 3 months

Exclusion Criteria:

- Treatment with external beam radiotherapy ≤ 14 days before enrollment or
radiopharmaceutical ≤8 weeks

- ≤ 4 weeks since receipt of most recent prior chemotherapy, non-GnRH analog hormonal
therapy (except for continuing corticosteroids) or other systemic therapy to treat
prostate cancer and <6 weeks since receipt of prior bevacizumab.

- Known CNS metastases (epidural disease is allowed if it has been treated and there is
no progression in the treated area).

- Significant cardiovascular disease

- LVEF < 50% by MUGA or ECHO

- Treatment of infection with systemic anti-infectives within 7 days before enrollment
(with the exception of uncomplicated urinary tract infection)

- Concurrent or prior (within 7 days of enrollment) anticoagulation therapy, except
that use of low dose coumarin-type anticoagulants or heparins for prophylaxis against
central venous catheter thrombosis is allowed

- Major surgical procedure ≤30 days before enrollment or not yet recovered from prior
major surgery

- Presence of peripheral edema > Grade 2

- Known positive test for HIV, hepatitis C, chronic or active hepatitis B

- Serious or non-healing wound

- Unable to begin protocol specified treatment within 7 days after enrollment

- Other investigational procedures are excluded.